Chris led the Pathology Dept at Peterborough Hospital where he was fundamentally responsible for setting up the first UK gold-standard human tissue bank. In addition he played an advisory role for the Human Tissue Authority where he helped to identify accepted guidelines for the use of human tissue in research. Chris is currently Honorary Professor, Cancer Studies Research Group at MCRC Biobank (University of Manchester) and recently retired Principal Clinical Histopathologist at AstraZeneca.
David has fulfilled many roles within research and diagnostic environments involving specialised histological technologies before joining Inveresk Research International (now part of the Charles River group). Here David set up and developed a department dedicated to providing new and existing histology and immunological technologies in support of the company’s regulatory preclinical toxicology safety testing. In this role he was the first person in the UK to offer human Tissue Cross-Reactivity studies for therapeutic Monoclonal antibodies to GLP standards. Having moved to take on a role involved in the development of predictive cell signalling biomarkers with Source BioScience he currently is responsible for business development and also is the Director of Histology and Quality Assurance.
Having begun his scientific career within the diagnostic environment of the Pathology Department of Leicester Royal Infirmary Andrew subsequently joined Huntingdon Life Science as Head of Specialised Histological Techniques and introduced and developed a range of specialised histology technologies including Immunohistochemistry, in particular human tissue cross-reactivity testing. Before setting up HistologiX Ltd Andrew joined David Fairley at Source Bioscience where he was involved with the development of cell signalling biomarkers. Andrew is currently responsible for all immunohistochemistry-based projects and together with David Fairley have a wealth of knowledge of screening many different types of antibody and non-antibody based molecules.
Histologix provides the Pharmaceutical and Biotechnology industry with specialist pathology services to assist drug development programmes ranging from Discovery, regulatory preclinical safety testing through to clinical trials and include human tissue sourcing, histology, medical and veterinary histopathology, immunohistochemistry, digital pathology and image analysis. These are technologies that have been developed with to meet current and future requirements of targeted therapy.
Through inward investment the services provided by Histologix Ltd use a range of highly sophisticated technologies and platforms aimed at standardising the various processes involved in order to achieve data generation that is consistent, accurate and reproducible and will assist our clients in the development of their drug programmes.
Histologix is a privately owned contract research organisation that provides specialist pathology services for the Pharmaceutical and Biotechnology industry. Set up in 2005 by industry specialists, Histologix is a GLP/GCP accredited, HTA-licenced company with an extensive and impressive track record of successfully delivering a range of IHC/ISH assays to large and small Pharma/Biotechnology companies and is a preferred supplier of these services to a number of companies.
Find out which conference Histologix is exhibiting at, updated news issues and current vacancies.